BioArctic Deal History & Licensing Activity
BioArctic is a biotech headquartered in Sweden. Over the past three years, BioArctic has been involved in 4 licensing and acquisition transactions, with a primary focus on Antibodies (4 deals).
Deals (12mo)
2
Active Trials
1
Top Modality
Antibodies
Focus Area
Neurology
BioArctic Recent Deal Activity
Licensing, acquisition, and partnership transactions involving BioArctic in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| BrainTransporter platform / Mesenkia antibody | Mesenkia Therapeutics | Antibodies | Discovery | collaboration | Aug 19, 2026 |
| BrainTransporter technology | Eli Lilly | Other | Discovery | collaboration | Jun 22, 2026 |
BioArctic Pipeline Focus
Therapeutic areas and modalities where BioArctic is most active based on deal history and clinical trial data.
Modalities
BioArctic Strategic Signals
Key indicators of BioArctic's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches BioArctic's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Neurology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About BioArctic Licensing & Deal Activity
BioArctic is a biotech company based in Sweden that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, BioArctic ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for BioArctic include Neurology (4 deals and trials), and Oncology (2 deals and trials). In terms of modality, BioArctic has shown particular interest in antibodies, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for BioArctic and 700+ other biopharma companies. Use our Solidus to benchmark your asset against BioArctic's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.